Referencias bibliográficas

1. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi J E, Pirko I, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710-21. [Pubmed]
2. Popescu BFG, Lucchinetti CF. Pathology of Demyelinating Diseases. Annu Rev Pathol Mech Dis. 2012;7(1):185-217. [Pubmed]
3. Popescu BFG, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Contin Lifelong Learn Neurol. 2013;19(4):901-21. [Pubmed]
4. Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia. 2014;62(11):1816-30. [Pubmed]
5. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(5):1175-89. [Pubmed]
6. Metz I, Weigand SD, Popescu BFG, Frischer JM, Parisi J, Guo Y, et al. Pathologic Heterogeneity Persists in Early Active Multiple Sclerosis Lesions. Ann Neurol. 2014;75(5):728-38. [Pubmed]
7. Lucchinetti C, Bruck W, Parisi J, Bernd S, Moses R, Hans L. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2001;47(6):707-17. [Pubmed]
8. Popescu BFG, Lucchinetti CF. Meningeal and cortical grey matter pathology in MS. BMC Neurol. 2012;12:11. [Pubmed]
9. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-97. [Pubmed]
10. Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012;11(4):349-60. [Pubmed]
11. Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees M, Magliozzi R, et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol. 2018;84(6):829-42. [Pubmed]
12. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68(9):634-42. [Pubmed]
13. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206:165-71. [Pubmed]
14. Geurts JJG, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008;7:841-51. [Pubmed]
15. Moreno Torres I, García-Merino A. Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother. 2017;17(4):359-71. [Pubmed]
16. Gilmore CP, Bö L, Owens T, Lowe J, Esiri MM. Spinal Cord Gray Matter Demyelination in Multiple Sclerosis-A Novel Pattern. Brain Pathol. 2006;16:202-8. [Pubmed]
17. Nijeholt GJ, Bergers E, Kamphorst W, Bot J, Nicolay K, Castelijns JA, et al. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. Brain. 2001;124(Pt 1):154-66. [Pubmed]
18. Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaits S, et al. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol. 2018;17(10):870-84. [Pubmed]
19. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodríguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain. 1999;122(12):2279-95. [Pubmed]
20. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti C, Sorensen PS, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010;133(10):2983-98. [Pubmed]
21. Strijbis EMM, Kooi E-J, van der Valk P, Geurts JJG. Cortical Remyelination Is Heterogeneous in Multiple Sclerosis. J Neuropathol Exp Neurol. 2017;76(5):390-401. [Pubmed]